{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:31:59Z","timestamp":1792729919269,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274013"],"award-info":[{"award-number":["82274013"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.phrs.2025.107706","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T21:50:48Z","timestamp":1742680248000},"page":"107706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Dual inhibition of hepatic ACLY and ACSS2: A synergistic approach to combat NAFLD through lipogenesis reduction and mitochondrial enhancement"],"prefix":"10.1016","volume":"215","author":[{"given":"Mengdi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujian","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlei","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maode","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixia","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.107706_bib1","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: how is it different from NAFLD?","volume":"29","author":"Gofton","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107706_bib2","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.phrs.2025.107706_bib3","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.phrs.2025.107706_bib4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.phrs.2025.107706_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2025.107706_bib6","article-title":"Lipid alterations in chronic liver disease and liver cancer","volume":"4","author":"Paul","year":"2022","journal-title":"JHEP Rep."},{"issue":"3","key":"10.1016\/j.phrs.2025.107706_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13733","article-title":"De novo lipogenesis in non-alcoholic fatty liver disease: quantification with stable isotope tracers","volume":"52","author":"Belew","year":"2022","journal-title":"Eur. J. Clin. Invest"},{"issue":"3","key":"10.1016\/j.phrs.2025.107706_bib8","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Invest"},{"issue":"4","key":"10.1016\/j.phrs.2025.107706_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41573-021-00367-2","article-title":"Lipogenesis inhibitors: therapeutic opportunities and challenges","volume":"21","author":"Batchuluun","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.phrs.2025.107706_bib10","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2023.10.042","article-title":"Pharmacologic inhibition of lipogenesis for the treatment of NAFLD","volume":"80","author":"Esler","year":"2024","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.phrs.2025.107706_bib11","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med"},{"issue":"9","key":"10.1016\/j.phrs.2025.107706_bib12","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41556-023-01198-6","article-title":"Malonyl-CoA is a conserved endogenous ATP-competitive mTORC1 inhibitor","volume":"25","author":"Nicastro","year":"2023","journal-title":"Nat. Cell Biol."},{"issue":"10","key":"10.1016\/j.phrs.2025.107706_bib13","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/cvr\/cvy089","article-title":"Increased cardiac fatty acid oxidation in a mouse model with decreased malonyl-CoA sensitivity of CPT1B","volume":"114","author":"van Weeghel","year":"2018","journal-title":"Cardiovasc Res."},{"issue":"2","key":"10.1016\/j.phrs.2025.107706_bib14","doi-asserted-by":"crossref","first-page":"E187","DOI":"10.1152\/ajpendo.00161.2022","article-title":"Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice","volume":"324","author":"Devereux","year":"2023","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2025.107706_bib15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cmet.2015.05.014","article-title":"Acetyl coenzyme a: a central metabolite and second messenger","volume":"21","author":"Pietrocola","year":"2015","journal-title":"Cell Metabol."},{"issue":"5","key":"10.1016\/j.phrs.2025.107706_bib16","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.molcel.2014.01.016","article-title":"Regulation of autophagy by cytosolic acetyl-coenzyme A","volume":"53","author":"Marino","year":"2014","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.phrs.2025.107706_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.molcel.2020.05.007","article-title":"Acetyl-CoA derived from hepatic peroxisomal beta-oxidation inhibits autophagy and promotes steatosis via mTORC1 activation","volume":"79","author":"He","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2025.107706_bib18","article-title":"A hierarchical hepatic de novo lipogenesis substrate supply network utilizing pyruvate, acetate, and ketones","author":"Rauckhorst","year":"2024","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.phrs.2025.107706_bib19","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.celrep.2016.09.069","article-title":"ATP-citrate lyase controls a glucose-to-acetate metabolic switch","volume":"17","author":"Zhao","year":"2016","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.phrs.2025.107706_bib20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia","volume":"34","author":"Morrow","year":"2022","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.phrs.2025.107706_bib21","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/HEP.0000000000000692","article-title":"Nuclear acly protects the liver from ischemia-reperfusion injury","volume":"80","author":"Gao","year":"2024","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.phrs.2025.107706_bib22","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1186\/s12967-023-04431-w","article-title":"ACLY as a modulator of liver cell functions and its role in metabolic dysfunction-associated Steatohepatitis","volume":"21","author":"Convertini","year":"2023","journal-title":"J. Transl. Med"},{"issue":"12","key":"10.1016\/j.phrs.2025.107706_bib23","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1124\/dmd.123.001449","article-title":"Bempedoic acid unveils therapeutic potential in non-alcoholic fatty liver disease: suppression of the hepatic PXR-SLC13A5\/ACLY signaling axis","volume":"51","author":"Sun","year":"2023","journal-title":"Drug Metab. Dispos."},{"issue":"31","key":"10.1016\/j.phrs.2025.107706_bib24","doi-asserted-by":"crossref","first-page":"8714","DOI":"10.1021\/acs.jafc.1c03105","article-title":"Regulation on citrate influx and metabolism through inhibiting SLC13A5 and ACLY: a novel mechanism mediating the therapeutic effects of curcumin on NAFLD","volume":"69","author":"Sun","year":"2021","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.phrs.2025.107706_bib25","article-title":"Acetate revisited: a key biomolecule at the nexus of metabolism, epigenetics, and oncogenesis - part 2: acetate and ACSS2 in Health and Disease","volume":"11","author":"Moffett","year":"2020","journal-title":"Front Physiol."},{"issue":"9","key":"10.1016\/j.phrs.2025.107706_bib26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.tcb.2019.05.005","article-title":"Acetate metabolism in physiology, cancer, and beyond","volume":"29","author":"Bose","year":"2019","journal-title":"Trends Cell Biol."},{"issue":"7800","key":"10.1016\/j.phrs.2025.107706_bib27","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-020-2101-7","article-title":"Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate","volume":"579","author":"Zhao","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.phrs.2025.107706_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102401","article-title":"Paradoxical activation of transcription factor SREBP1c and de novo lipogenesis by hepatocyte-selective ATP-citrate lyase depletion in obese mice","volume":"298","author":"Yenilmez","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107706_bib29","article-title":"Bempedoic acid suppresses diet-induced hepatic steatosis independently of ATP-citrate lyase","author":"Liu","year":"2024","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.phrs.2025.107706_bib30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41556-024-01372-4","article-title":"Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis","volume":"26","author":"Murthy","year":"2024","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107706_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cmet.2020.12.015","article-title":"The evolving landscape of noncanonical functions of metabolic enzymes in cancer and other pathologies","volume":"33","author":"Xu","year":"2021","journal-title":"Cell Metab."},{"issue":"9","key":"10.1016\/j.phrs.2025.107706_bib32","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.celrep.2017.02.006","article-title":"Extracellular acidic pH activates the sterol regulatory element-binding protein 2 to promote tumor progression","volume":"18","author":"Kondo","year":"2017","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.phrs.2025.107706_bib33","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.molcel.2017.04.026","article-title":"Nucleus-translocated ACSS2 promotes gene transcription for lysosomal biogenesis and autophagy","volume":"66","author":"Li","year":"2017","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.phrs.2025.107706_bib34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12967-024-04870-z","article-title":"Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K\/AKT\/mTOR pathway to promote the progression of pancreatic neuroendocrine neoplasms","volume":"22","author":"Gu","year":"2024","journal-title":"J. Transl. Med."},{"issue":"9","key":"10.1016\/j.phrs.2025.107706_bib35","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231820","article-title":"ACLY and ACSS2 link nutrient-dependent chromatin accessibility to CD8 T cell effector responses","volume":"221","author":"Kaymak","year":"2024","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.phrs.2025.107706_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23368","article-title":"Eriodictyol regulated ferroptosis, mitochondrial dysfunction, and cell viability via Nrf2\/HO-1\/NQO1 signaling pathway in ovarian cancer cells","volume":"37","author":"Wang","year":"2023","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"49","key":"10.1016\/j.phrs.2025.107706_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adi2465","article-title":"Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation","volume":"9","author":"Xiang","year":"2023","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.phrs.2025.107706_bib38","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cell.2018.08.040","article-title":"Acetate production from glucose and coupling to mitochondrial metabolism in mammals","volume":"175","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107706_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155914","article-title":"O-GlcNAcylation promotes the progression of nonalcoholic fatty liver disease by upregulating the expression and function of CD36","volume":"156","author":"Zhu","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2025.107706_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101428","article-title":"CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing","volume":"57","author":"Zeng","year":"2022","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2025.107706_bib41","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1038\/s41467-022-33349-y","article-title":"CD36-mediated metabolic crosstalk between tumor cells and macrophages affects liver metastasis","volume":"13","author":"Yang","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2025.107706_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010449","article-title":"Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis","volume":"24","author":"Rochette","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.phrs.2025.107706_bib43","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1016\/j.celrep.2018.08.031","article-title":"Mechanisms underlying the dual effect of polyunsaturated fatty acid analogs on Kv7.1","volume":"24","author":"Liin","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.phrs.2025.107706_bib44","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/hep.32148","article-title":"Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice","volume":"75","author":"Duan","year":"2022","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.phrs.2025.107706_bib45","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/s41467-024-51444-0","article-title":"The proto-oncogene tyrosine kinase c-SRC facilitates glioblastoma progression by remodeling fatty acid synthesis","volume":"15","author":"Zhao","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825001318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825001318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T15:32:22Z","timestamp":1745681542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825001318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":45,"alternative-id":["S1043661825001318"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107706","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual inhibition of hepatic ACLY and ACSS2: A synergistic approach to combat NAFLD through lipogenesis reduction and mitochondrial enhancement","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107706"}}